Druggability & Clinical Context
Druggability
Low
Score: 0.43
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
5
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
Druggability Rationale: ST6GAL1 presents moderate druggability (0.55 score) as an enzyme target with a well-defined catalytic domain and multiple available crystal structures (5 PDB entries at 1.6 Å resolution). However, the limited clinical translation (only tool compounds and no approved drugs) and the challenge of achieving selective sialyltransferase inhibition without off-target glycosylation effects temper optimization prospects.
Mechanism: ST6GAL1 inhibitors would block the addition of α2,6-linked sialic acids to N-glycans on cell surface proteins, altering immune cell recognition and potentially enhancing anti-tumor immunity or modulating inflammatory responses. This glycosylation modification is crucial for immune evasion in cancer and autoimmune disease pathogenesis.
Drug Pipeline (2 compounds)
Known Drugs:3Fax-Peracetyl Neu5Ac (tool_compound) — research inhibitor
Lithocholic acid (tool_compound) — research inhibitor
Structural Data:PDB (5) ✓AlphaFold ✓Cryo-EM —
Selectivity & Safety Considerations
Selectivity remains a key challenge given the presence of multiple sialyltransferase isoforms (ST6GAL1 vs. ST6GAL2, ST3GAL family) with overlapping substrate specificity; achieving selective α2,6-sialylation inhibition without disrupting other glycosylation pathways is critical to avoid broad immunological or developmental toxicities.